133 related articles for article (PubMed ID: 28937402)
1. Effect of processing time on analysis of rare event in minimal residual disease study.
Rai S; Bhardwaj U; Singh S; Misra A
Indian J Pathol Microbiol; 2017; 60(3):449-451. PubMed ID: 28937402
[No Abstract] [Full Text] [Related]
2. Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization.
Schuurhuis GJ; Ossenkoppele GJ; Kelder A; Cloos J
Expert Rev Hematol; 2018 Dec; 11(12):921-935. PubMed ID: 30466339
[No Abstract] [Full Text] [Related]
3. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
Feng JH; Xu XJ; Tang YM
Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
[No Abstract] [Full Text] [Related]
4. Combining flow cytometry and
Guolo F; Minetto P; Clavio M; Miglino M; Galaverna F; Raiola AM; Di Grazia C; Colombo N; Pozzi S; Ibatici A; Bagnasco S; Guardo D; Kunkl A; Ballerini F; Ghiggi C; Lemoli RM; Gobbi M; Bacigalupo A
Haematologica; 2017 Sep; 102(9):e348-e351. PubMed ID: 28495917
[No Abstract] [Full Text] [Related]
5. A refined approach to detect and measure minimal residual disease in childhood acute myeloid leukemia by flow cytometry.
Capolunghi F; Capponi C; De Stefani B; Luciani M; Locatelli F; Muraca M; Carsetti R
Am J Hematol; 2014 Mar; 89(3):343-4. PubMed ID: 24265183
[No Abstract] [Full Text] [Related]
6. How Do We Use Multicolor Flow Cytometry to Detect Minimal Residual Disease in Acute Myeloid Leukemia?
Xu J; Jorgensen JL; Wang SA
Clin Lab Med; 2017 Dec; 37(4):787-802. PubMed ID: 29128069
[TBL] [Abstract][Full Text] [Related]
7. Minimal Residual Disease in Acute Myeloid Leukemia.
Sung PJ; Luger SM
Curr Treat Options Oncol; 2017 Jan; 18(1):1. PubMed ID: 28110381
[TBL] [Abstract][Full Text] [Related]
8. Readying the minimal residual disease concept in acute myeloid leukaemia for prime time - the American way.
Hokland P; Cotter F
Br J Haematol; 2013 Aug; 162(4):429-30. PubMed ID: 23772825
[No Abstract] [Full Text] [Related]
9. Monitoring minimal residual disease in AML.
Stewart CC
Cytotherapy; 1999; 1(4):341. PubMed ID: 20426562
[No Abstract] [Full Text] [Related]
10. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
Kern W; Haferlach T
Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
[TBL] [Abstract][Full Text] [Related]
11. Defining patient-specific risk in acute myeloid leukemia.
Ho TC; Becker MW
J Clin Oncol; 2013 Nov; 31(31):3857-9. PubMed ID: 24062389
[No Abstract] [Full Text] [Related]
12. Flow cytometric monitoring of residual disease in acute leukemia.
Wood BL
Methods Mol Biol; 2013; 999():123-36. PubMed ID: 23666694
[TBL] [Abstract][Full Text] [Related]
13. The minimal residual disease concept coming of age - now for the direct comparison of methodologies.
Ommen HB; Roug AS; Hokland P
Leuk Res; 2012 Apr; 36(4):392-3. PubMed ID: 22261230
[No Abstract] [Full Text] [Related]
14. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of a 10-color flow cytometry panel to detect measurable residual disease in acute myeloid leukemia.
Ikoma-Colturato MRV; Severino AR; Dos Santos Tosi JF; Bertolucci CM; Cuoco YMN; de Mattos ER; Colturato I; Silva FBR; de Souza MP; Simione AJ; Colturato VAR
Leuk Res; 2024 May; 140():107482. PubMed ID: 38552548
[No Abstract] [Full Text] [Related]
16. Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.
Jorgensen JL; Chen SS
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S49-53. PubMed ID: 22035748
[TBL] [Abstract][Full Text] [Related]
17. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia.
Chevillon F; Clappier E; Arfeuille C; Cayuela JM; Dalle JH; Kim R; Caye-Eude A; Chalas C; Abdo C; Drouineaud V; Peffault de Latour R; Alcantara M; Uzunov M; Degaud M; Meignin V; Dombret H; Boissel N; Poirot C; Dhédin N
Blood; 2021 Mar; 137(12):1697-1701. PubMed ID: 33171484
[No Abstract] [Full Text] [Related]
19. Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia.
Sorigue M; Espasa A; Zamora L; Junca J
Ann Hematol; 2020 May; 99(5):1135-1136. PubMed ID: 32170360
[No Abstract] [Full Text] [Related]
20. Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults.
Freeman SD; Hills RK; Russell NH; ; Cloos J; Kelder A; Ossenkoppele GJ; Schuurhuis GJ;
Br J Haematol; 2019 Jul; 186(1):130-133. PubMed ID: 30520018
[No Abstract] [Full Text] [Related]
[Next] [New Search]
